Servier Acquires Muscular Dystrophy Business for Up to $2.7 Billion
French pharmaceutical company Servier has agreed to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal worth up to $2.7 billion, including an upfront payment and potential milestone payments.
Tickers: $EWTX
Topics: acquisition biotechnology muscular dystrophy pharmaceuticals